Taulant Muka1, Fjorda Koromani2, Eliana Portilla3, Annalouise O'Connor4, Wichor M Bramer5, John Troup4, Rajiv Chowdhury6, Abbas Dehghan3, Oscar H Franco3. 1. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: t.muka@erasmusmc.nl. 2. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. 3. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. 4. Research and Development, Metagenics, Inc., United States. 5. Medical Library, Erasmus University Medical Center, Rotterdam, the Netherlands. 6. Department of Public Health & Primary Care, Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge CB1 8RN, United Kingdom.
Abstract
BACKGROUND: Epigenetic modifications of the genome, such as DNA methylation and histone modifications, have been reported to play a role in processes underlying cardiovascular disease (CVD), including atherosclerosis, inflammation, hypertension and diabetes. METHODS: Eleven databases were searched for studies investigating the association between epigenetic marks (either global, site-specific or genome-wide methylation of DNA and histone modifications) and CVD. RESULTS: Of the 3459 searched references, 31 studies met our inclusion criteria (26 cross-sectional studies and 5 prospective studies). Overall, 12,648 individuals were included, with total of 4037 CVD events. The global DNA methylation assessed at long-interspersed nuclear element (LINE-1) was inversely associated with CVD, independent of established cardiovascular risk factors. Conversely, a higher degree of global DNA methylation measured at Alu repeats or by the LUMA method was associated with the presence of CVD. The studies reported epigenetic regulation of 34 metabolic genes (involved in fetal growth, glucose and lipid metabolism, inflammation, atherosclerosis and oxidative stress) in blood cells to be related with CVD. Among them, 5 loci were validated and methylation at F2RL3 was reported in two large prospective studies to predict cardiovascular disease beyond the traditional risk factors. CONCLUSIONS: Current evidence supports an association between genomic DNA methylation and CVD. However, this review highlights important gaps in the existing evidences including lack of large-scale epigenetic investigations, needed to reliably identify genomic loci where DNA methylation is related to risk of CVD.
BACKGROUND: Epigenetic modifications of the genome, such as DNA methylation and histone modifications, have been reported to play a role in processes underlying cardiovascular disease (CVD), including atherosclerosis, inflammation, hypertension and diabetes. METHODS: Eleven databases were searched for studies investigating the association between epigenetic marks (either global, site-specific or genome-wide methylation of DNA and histone modifications) and CVD. RESULTS: Of the 3459 searched references, 31 studies met our inclusion criteria (26 cross-sectional studies and 5 prospective studies). Overall, 12,648 individuals were included, with total of 4037 CVD events. The global DNA methylation assessed at long-interspersed nuclear element (LINE-1) was inversely associated with CVD, independent of established cardiovascular risk factors. Conversely, a higher degree of global DNA methylation measured at Alu repeats or by the LUMA method was associated with the presence of CVD. The studies reported epigenetic regulation of 34 metabolic genes (involved in fetal growth, glucose and lipid metabolism, inflammation, atherosclerosis and oxidative stress) in blood cells to be related with CVD. Among them, 5 loci were validated and methylation at F2RL3 was reported in two large prospective studies to predict cardiovascular disease beyond the traditional risk factors. CONCLUSIONS: Current evidence supports an association between genomic DNA methylation and CVD. However, this review highlights important gaps in the existing evidences including lack of large-scale epigenetic investigations, needed to reliably identify genomic loci where DNA methylation is related to risk of CVD.
Authors: Anna C Blice-Baum; Maria Clara Guida; Paul S Hartley; Peter D Adams; Rolf Bodmer; Anthony Cammarato Journal: Biochim Biophys Acta Mol Basis Dis Date: 2018-11-27 Impact factor: 5.187
Authors: Veronica Barcelona de Mendoza; Yunfeng Huang; Cindy A Crusto; Yan V Sun; Jacquelyn Y Taylor Journal: Biol Res Nurs Date: 2017-12-19 Impact factor: 2.522
Authors: Jian V Huang; Andres Cardenas; Elena Colicino; C Mary Schooling; Sheryl L Rifas-Shiman; Golareh Agha; Yinan Zheng; Lifang Hou; Allan C Just; Augusto A Litonjua; Dawn L DeMeo; Xihong Lin; Emily Oken; Marie-France Hivert; Andrea A Baccarelli Journal: Epigenetics Date: 2018-11-13 Impact factor: 4.528